FICHIT

Je m'inscris

VALBIOTIS

0/5 (0 note(s))
Note donnée : aucune
Paris
0
Discovers and develops global health solutions from prevention to treatment against cardiometabolic diseases
For its solution to prevent Type 2 Diabetes, VALBIOTIS finished its preclinical studies at the end of 2015 with spectacular results. VALBIOTIS will begin in January 2016 a safety study and in March 2016 a double-blind, randomized, multicenter controlled study in 80 abdominally obese patients with combined dyslipidemia and prediabetes.
VALBIOTIS will continue in 2016 is preclinical studies to develop a new drug to treat type 2 diabetes and its complication
PELTIER Sébastien
www.valbiotis.com
Private Equity

Fiche créée le 10/04/2016 par Guillaume   vue 13 fois.